Wedbush Reiterates Outperform on Monte Rosa Therapeutics, Maintains $27 Price Target

Benzinga Newsdesk www.benzinga.com Negative 76.5%

Neg 76.5% Neu 0% Pos 0%

Wedbush analyst Robert Driscoll reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Outperform and maintains $27 price target.